Latest
finance.yahoo.com Regulatory and legal
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
Junshi Biosciences SHANGHAI, July 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental application for toripalimab in combination with platinum-containing chemotherapy as perioperative treatment and subsequent monotherapy as adjuvant therapy for the …